GlassScriptPhysician profile
Clifton Patrick Layman
NPI 1528353075
$645,185.11
in general payments reported to CMS, 2019-2025
60 companies · $226K in 2025
The $226K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $36.89 · 2021: $8,403 · 2022: $79K · 2023: $130K · 2024: $202K · 2025: $226K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $443K · Travel and Lodging: $57K · Consulting Fee: $29K · Food and Beverage: $17K · Honoraria: $11K · Education: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $442,546.25 |
| Travel and Lodging | $57,225.03 |
| Consulting Fee | $28,907.00 |
| Food and Beverage | $17,102.62 |
| Honoraria | $11,122.50 |
| Education | $572.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $246,550.59 | 2020-2025 | Lynparza, Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $174,124.45 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $119,239.59 | 2022-2025 | Libtayo |
| Genzyme Corporation | $50,179.08 | 2021-2025 | |
| Daiichi Sankyo INC. | $34,275.70 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Karyopharm Therapeutics INC. | $9,867.17 | 2022-2025 | Xpovio |
| Exelixis INC. | $3,402.70 | 2023-2025 | Cabometyx |
| Celgene Corporation | $1,115.76 | 2021-2025 | Reblozyl, Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $947.08 | 2022-2025 | |
| Janssen Biotech, INC. | $625.04 | 2022-2025 | Rybrevant, Carvykti, Talvey |
| Gilead Sciences, INC. | $577.26 | 2022-2025 | Trodelvy |
| Astellas Pharma US INC | $297.56 | 2023-2025 | Xtandi |
| Incyte Corporation | $284.69 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $274.61 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Genmab U.S., INC. | $251.25 | 2023-2025 | Epkinly, Tivdak |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $218.24 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $218.17 | 2022-2025 | |
| Abbvie INC. | $215.95 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.39 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.80 | 2022-2025 | Iclusig, Alunbrig, Hyqvia |
| Eisai INC. | $146.71 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $144.67 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $143.99 | 2022-2024 | |
| Mirati Therapeutics, INC. | $133.86 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $123.17 | 2022-2025 | Yescarta |
| Emd Serono, INC. | $107.32 | 2023-2025 | Tepmetko |
| Seagen INC. | $107.18 | 2022-2023 | Adcetris, Tukysa |
| Amgen INC. | $104.60 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Puma Biotechnology, INC. | $97.69 | 2022-2025 | |
| Tersera Therapeutics LLC | $88.15 | 2023-2025 | Zoladex |
| Stemline Therapeutics INC. | $86.79 | 2023-2025 | Orserdu |
| Tempus Ai, INC | $83.55 | 2024-2025 | Xt Cdx |
| Array Biopharma INC | $71.44 | 2023-2024 | Lorbrena, Braftovi, Mektovi |
| Caris Mpi, INC. | $58.54 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $52.09 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Lilly USA, LLC | $51.19 | 2023 | Retevmo, Jaypirca, Verzenio |
| Blueprint Medicines Corporation | $43.14 | 2024 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $42.15 | 2022-2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.82 | 2025 | |
| Sobi, INC | $35.47 | 2023 | |
| Cti Biopharma Corp. | $32.89 | 2022-2023 | Vonjo |
| Ipsen Biopharmaceuticals, INC | $31.79 | 2021 | |
| Dendreon Pharmaceuticals LLC | $30.02 | 2024 | Provenge |
| Geron Corporation | $29.36 | 2025 | Rytelo |
| Taiho Oncology, INC. | $28.45 | 2022-2023 | |
| Menarini Silicon Biosystems, INC. | $24.72 | 2025 | |
| Myovant Sciences INC. | $23.76 | 2022 | |
| Springworks Therapeutics, INC. | $23.45 | 2024 | Ogsiveo |
| Acrotech Biopharma INC. | $22.69 | 2024 | Beleodaq |
| Azurity Pharmaceuticals, INC. | $22.63 | 2025 | Danziten |
| Nuvation Bio INC. | $21.40 | 2025 | Ibtrozi |
| Progenics Pharmaceuticals, INC. | $20.60 | 2023 | Pylarify |
| Servier Pharmaceuticals LLC | $18.65 | 2024 | |
| Kyowa Kirin, INC. | $18.08 | 2022 | |
| Aveo Pharmaceuticals, INC. | $17.50 | 2023 | Fotivda |
| Glaxosmithkline, LLC. | $16.41 | 2024 | Ojjaara |
| Adaptive Biotechnologies Corporation | $16.11 | 2025 | Clonoseq |
| Fresenius Kabi USA, LLC | $13.70 | 2024 | Stimufend |
| Morphosys, US INC. | $13.48 | 2022 | |
| Pharmacosmos Therapeutics INC. | $12.82 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifton Layman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.